Tag Archives | Stockholm Cancer Congress

Alpharadin may change standard of care for prostate cancer patients with bone mets

We recently attended the 2011 European Multidisciplinary Cancer Congress in Stockholm. Paradigm shifting data in breast cancer and advanced prostate cancer were presented at what turned out to be an excellent meeting in a charming, if expensive, city. Pieter Droppert (@3NT) has written several posts on biotech strategy blog about the exciting data for radium-223 […]

Continue Reading

Vismodegib best abstract at ECCO 2011 Stockholm Cancer Congress

Next week sees the start of the 2011 Stockholm Cancer Congress – a joint multidisciplinary meeting of ECCO, ESMO and ESTRO. What’s likely to be hot news from Stockholm? On Biotech Strategy Blog, Pieter Droppert has highlighted the phase III data to be presented at ECCO 2011 on Alpharadin (radium-223 chloride) in castration-resistant prostate cancer […]

Continue Reading

ECCO ESMO Stockholm Cancer Conference September 2011

Summer is almost over, and thoughts at Icarus Consultants are now turning to forthcoming medical meetings that we will be attending. You can access the preliminary programme for the meeting here. Given the early cut-off date for submission of abstracts for the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, we expect the […]

Continue Reading

error: Content is protected !!